Sengenics Partners with Sequenom to Launch VisibiliT in Asia | GenomeWeb

NEW YORK (GenomeWeb) – Sengenics said this week that it has exclusively partnered with Sequenom to launch that company's VisibiliT non-invasive prenatal test in Thailand, Indonesia, and Brunei.

VisibiliT targets women with average-risk pregnancies and has a lower cost and content than Sequenom's MaterniT21 Plus NIPT. Using a maternal blood sample, it analyzes chromosomal material in cell-free DNA of pregnant women to provide information about common fetal trisomies. The test reports a risk score for trisomies 21, 18, and 13, as well as fetal gender.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.